Saturday 17 October 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.10
0.21
−6.34%
Follow CLNN
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 1 | 3 | 3 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (1.55) | — | (2.30) | — | (8.30) | (8.24) | (17.56) | (27.14) |
P/S ratio |
— | 0.00 | 919.38 | 643.23 | 349.08 | 376.33 | 130.96 | 46.53 | 107.97 | 289.36 |
Altman Z″-Score (non-manufacturers) |
— | — | (4.39) | — | (8.45) | — | (19.12) | (18.27) | (40.63) | (65.16) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | 2.04 | — | 2.66 | (4.26) | (6.10) | — |
P/Operating CF |
— | (14.29) | (32.61) | (22.81) | (26.27) | (28.32) | (8.03) | (4.24) | (7.59) | (12.06) |
P/B ratio |
— | 0.00 | 555.41 | 388.58 | 20.04 | 21.60 | 19.14 | 2.27 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 555.41 | 388.58 | 20.04 | 21.60 | 19.14 | 2.27 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 642.10 | 365.94 | 306.06 | 333.30 | 122.45 | 11.45 | 117.53 | 331.12 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (13.20) | (6.99) | (3.98) | (6.39) | (6.96) | (1.48) | (0.25) | (1.88) | (3.57) |
EV/FCF |
— | (13.20) | (6.85) | (3.90) | (6.15) | (6.70) | (1.31) | (0.25) | (1.88) | (3.56) |
Quick Ratio |
2.04 | 5.27 | 5.08 | 8.61 | 8.35 | 1.90 | 1.70 | 1.39 | 1.19 | 0.48 |
Current Ratio |
2.20 | 5.40 | 5.40 | 9.06 | 9.06 | 2.11 | 2.11 | 1.53 | 1.57 | 0.83 |
Net Debt/EBITDA |
0.50 | 2.88 | 2.97 | 0.55 | 0.63 | (0.03) | 0.09 | 0.59 | (0.10) | (0.39) |
Debt/Assets |
6.92% | 5.77% | 3.16% | 37.34% | 30.41% | 55.84% | 43.35% | 23.03% | 56.43% | 74.68% |
Debt/Equity |
(0.02) | 11.55 | 6.32 | 1.87 | 1.52 | 7.68 | 5.96 | 0.90 | (1.74) | (0.77) |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Operating CF/Net income |
0.82 | 0.98 | 0.98 | 3.55 | 3.55 | 1.30 | 1.30 | 0.61 | 0.54 | 0.71 |
Capex/Depreciation |
(0.35) | 0.00 | (0.40) | 0.00 | (1.39) | 0.00 | (5.08) | (0.19) | (0.01) | (0.03) |
Interest Coverage |
(185.59) | — | (21.28) | — | (57.45) | — | (14.69) | (8.89) | (8.14) | (8.61) |
| 51.47% | 0.00% | 57.17% | 0.00% | (150.56%) | 0.00% | (377.90%) | (595.47%) | (1,738.36%) | 197.91% | |
| (52.08%) | 0.00% | (46.38%) | 0.00% | (14.84%) | 0.00% | (55.63%) | (102.25%) | (98.90%) | (115.13%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(170.38%) | (34.07%) | (34.70%) | (17.09%) | (18.13%) | (97.84%) | (115.18%) | (217.27%) | (295.24%) | (619.63%) |
Average Days of Receivables |
— | 3,843.13 | 37.21 | 814.31 | 24.74 | 2,288.77 | 145.85 | 79.81 | 68.30 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 6,943.69% | 7,380.58% | 3,819.64% | 3,930.29% | 6,581.40% | 6,748.41% | 4,075.69% | 5,864.91% | 7,005.50% |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,451.94% | 2,500.49% | 3,028.49% | 3,042.32% | 3,449.89% | 3,580.55% | 2,204.59% | 3,890.94% | 4,614.50% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 369.42% | 0.00% | 1,712.86% | 0.00% | 1,799.79% | 1,394.04% | 2,325.44% | 3,191.00% |
Graham Net Nets |
— | (0.40) | (0.03) | (0.04) | 0.02 | 0.02 | (0.19) | 0.00 | (0.54) | (0.46) |
Graham Number |
— | 0.00 | 0.00 | 90.61 | 0.00 | 8.99 | 0.00 | 0.00 | 12.84 | 10.22 |
Earnings Yield |
— | (11.34%) | (10.18%) | (14.55%) | (4.15%) | (3.85%) | (47.37%) | (179.31%) | (108.29%) | (44.29%) |
Free Cash Flow Yield |
— | (7.25%) | (10.20%) | (14.58%) | (14.25%) | (13.21%) | (71.34%) | (100.23%) | (57.79%) | (32.12%) |
Revenue per Share |
0.00 | 0.01 | 0.24 | 0.01 | 0.23 | 0.01 | 0.15 | 0.12 | 0.05 | 0.02 |
Operating CF per Share |
(15.21) | (1.08) | (21.63) | (0.56) | (11.25) | (0.60) | (11.97) | (5.75) | (3.07) | (1.88) |
Capex per Share |
(0.34) | 0.00 | (0.44) | 0.00 | (0.43) | 0.00 | (1.59) | (0.06) | 0.00 | 0.00 |
Free Cash Flow per Share |
(15.54) | (1.08) | (22.07) | (0.56) | (11.68) | (0.60) | (13.55) | (5.81) | (3.07) | (1.89) |
Cash per Share |
10.13 | 3.39 | 67.73 | 0.82 | 16.34 | 0.36 | 7.15 | 6.67 | 1.75 | 0.53 |
Shareholders Equity per Share |
(78.09) | 0.02 | 0.39 | 0.20 | 4.09 | 0.05 | 0.99 | 2.55 | (1.27) | (1.78) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(78.09) | 0.02 | 0.39 | 0.20 | 4.09 | 0.05 | 0.99 | 2.55 | (1.27) | (1.78) |
Free Cash Flow |
(13.49) | (18.93) | (19.32) | (34.62) | (35.96) | (39.01) | (44.19) | (30.50) | (21.34) | (18.58) |
Working Capital |
5.16 | 51.32 | 51.32 | 48.56 | 48.56 | 15.34 | 15.34 | 13.52 | 5.87 | (1.80) |
Capital Expenditures |
(0.29) | (0.39) | (0.39) | (1.33) | (1.33) | (5.18) | (5.18) | (0.33) | (0.01) | (0.04) |
Net Current Asset Value |
(73.17) | (4.91) | (4.91) | 4.12 | 4.12 | (12.06) | (12.06) | (0.10) | (20.04) | (26.75) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 1.88 | 0.00 | 1.84 | 0.00 | 10.95 | 0.50 | 0.04 | 0.20 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.18 | 0.23 | 0.11 | 0.18 | 0.09 | 0.10 | 0.18 | 0.22 | 0.25 |
Cash ROIC |
23.28% | (29.78%) | (31.27%) | (40.06%) | (43.81%) | (75.90%) | (96.40%) | (50.46%) | (113.98%) | (1,633.13%) |
Accounts Receivable Turnover |
— | 0.00 | 0.19 | 0.00 | 20.66 | 0.00 | 3.97 | 3.94 | 3.30 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.06 | 0.00 | 0.19 | 0.00 | 0.01 | 0.05 | 0.05 | 0.04 |
Inventory Turnover |
0.00 | 0.00 | 0.59 | 0.00 | 2.49 | 0.00 | 0.62 | 3.03 | 1.33 | 0.82 |
Average Days of Payables |
0.00 | 385.22 | 6,311.69 | 590.32 | 2,428.70 | 767.16 | 42,311.92 | 4,536.86 | 6,465.71 | 7,571.63 |
Days of Inventory on Hand |
0.00 | 65.46 | 1,072.54 | 12.59 | 51.78 | 10.94 | 603.65 | 111.61 | 354.57 | 314.07 |
Average Receivables |
— | 1.10 | 1.10 | 0.82 | 0.04 | 1.51 | 0.12 | 0.17 | 0.10 | — |
Average Payables |
0.89 | 1.01 | 1.01 | 1.52 | 1.52 | 2.47 | 2.47 | 2.26 | 1.37 | 1.07 |
Average Inventory |
0.03 | 0.11 | 0.11 | 0.12 | 0.12 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 |
Average Assets |
31.02 | 41.56 | 41.56 | 65.65 | 65.65 | 53.78 | 53.78 | 48.42 | 39.84 | 22.73 |
Average Common Equity |
(31.39) | (33.72) | (33.72) | 6.47 | 6.47 | 7.92 | 7.92 | 8.31 | 2.27 | (13.22) |
Columns are period end dates